Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Adderall XR

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

- PMLiVE

Pfizer concludes NextWave acquisition

Sets company up to compete in the ADHD sector

- PMLiVE

Shire promotes Dr Jeff Jonas to lead regenerative medicines business

His former role leading specialty pharma R&D will be filled by Arnaud Partiot

- PMLiVE

Shire picks Bayer’s Flemming Ornskov as new head

He will succeed Angus Russell who is retiring next year

- PMLiVE

Pfizer pays $680m to buy ADHD drug developer NextWave

Portfolio includes once-daily Quillivant XR

- PMLiVE

Targacept to cut more jobs after ADHD trial failure

TC-5619 disappoints in phase II trial after missing primary endpoint

- PMLiVE

Dr Steven Gillis joins Shire’s board of directors

He will sit on the pharma firm's science and technology and its remuneration committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links